Findings show a significant increase in NAD+ levels and within-group benefits in fatigue, depression, and sleep quality Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal eClinicalMedicine demonstrating that daily supplementation with Niagen®, Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, significantly increased NAD+ levels and improved executive functioning, fatigue, depression, and sleep quality, when compared to their baseline levels, in some i

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding common stock over approximately 24 months (the "Program"). "We believe Niagen Bioscience is an excellent investment and the Program is a compelling use of the company's capital presently," said Rob Fried, Chief Executive Officer of Niagen Bioscience. Under the Program, Niagen Bioscience may repurchase shares in the open market, through privately negotiated transactions or oth

Net sales increased 33% to $34.0 million Gross margin increased 100 bps to 64.5% Net income of $4.6 million, up $2.7 million from the prior year Adjusted EBITDA increased by 120% to $6.4 million Full year 2025 net sales outlook of 25% to 30% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%. Gross margin increased 100 basis points to 64.5%. Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points.

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November 4, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the third quarter 2025 financial results and provide a general business update on Tuesday, November 4, 2025, at 4:

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has increased its full-year 2025 net sales outlook to 25% to 30% year-over-year growth from 22% to 27%. "Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of science is valuable for public health and for Niagen Bioscience," remarked Rob Fried, CEO of Niagen Bioscience. "We believe the FDA's latest reversal of previous rulings on the DSHEA drug preclusion rule relating to NMN could serve to increase awareness of the NAD+ precursor market overall and the safety and effi

Niagen IV and injections perfectly align NAD+-boosting science with iCRYO's mission to deliver solutions for recovery, performance, and healthy aging Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that pharmaceutical-grade Niagen Plus™ products, Niagen IV and injections, are now offered at more than 50 iCRYO locations across the U.S., bringing availability to more than 900 clinics nationwide. The partnership aligns Niagen Bioscience's innovative, science-backed, pharmaceutical-grade NAD+-boosting Niagen products with iCRYO's clientele, who seek accessible, preventative so

A premier resource for NAD+ science—highlighting nicotinamide riboside (NR)—the newly evolved site features peer-reviewed studies, educational content, and a categorized research library. Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today unveils the newly evolved AboutNADⓇ, a centralized educational resource and published research database detailing scientific advancements in NAD+ biology and its role in human health. Guided by the mission of empowering health through scientific education, the new and improved site distills peer-reviewed findings on NAD+ with a focus on the most effic

Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin

Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit www.wsw.com. Mr. Fried and Mr. Pamir will also hold one-on-one meetings with instituti

Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, Aug